TORISEL™ Kit
(temsirolimus injection)
Temsirolimus, an inhibitor of mTOR, is an antineoplastic agent.
Temsirolimus is a white to off-white powder with a molecular formula of C56H87NO16 and a molecular weight of 1030.30. It is non-hygroscopic. Temsirolimus is practically insoluble in water and soluble in alcohol. It has no ionizable functional groups, and its solubility is independent of pH.
The chemical name of temsirolimus is
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,10,12,13,14,21,22,23,24,25, 26,27,32,33,34,34a-Hexadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]-1-methylethyl]-10,21-dimethoxy-6,8,12,14,20,26-hexameth3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone 4′-[2,2-bis(hydroxymethyl)propionate]; or Rapamycin, 42-[3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate].
 |
TORISEL (temsirolimus) injection, 25 mg/mL, is a clear, colorless to light-yellow, non-aqueous, ethanolic, sterile solution. TORISEL (temsirolimus) injection requires two dilutions prior to intravenous infusion. TORISEL (temsirolimus) injection should be diluted only with the supplied DILUENT for TORISEL.
DILUENT for TORISEL is a sterile, non-aqueous solution that is supplied with TORISEL injection, as a kit.
TORISEL (temsirolimus) injection, 25 mg/mL:
Active ingredient: temsirolimus (25 mg/mL)
Inactive ingredients: dehydrated alcohol (39.5% w/v), dl-alpha-tocopherol (0.075% w/v), propylene glycol (50.3% w/v), and anhydrous citric acid (0.0025% w/v).
DILUENT for TORISEL
Inactive ingredients: polysorbate 80 (40.0% w/v), polyethylene glycol 400 (42.8% w/v), and dehydrated alcohol (19.9%w/v).
After the TORISEL (temsirolimus) injection vial has been diluted with DILUENT for TORISEL, in accordance with the instructions in section 2.5, the solution contains 35.2% alcohol.
TORISEL (temsirolimus) injection and DILUENT for TORISEL are filled in clear glass vials with butyl rubber stoppers.
Last updated on RxList: 6/25/2007
The recommended dose of TORISEL for advanced renal cell carcinoma is 25 mg infused over a 30-60 minute period once a week.
Treatment should continue until disease progression or unacceptable toxicity occurs.
Patients should receive prophylactic intravenous diphenhydramine 25 to 50 mg (or similar antihistamine) approximately 30 minutes before the start of each dose of TORISEL [see Hypersensitivity Reactions].
TORISEL should be held for absolute neutrophil count (ANC) < 1,000/mm3, platelet count < 75,000/mm3, or NCI CTCAE grade 3 or greater adverse reactions. Once toxicities have resolved to grade 2 or less, TORISEL may be restarted with the dose reduced by 5 mg/week to a dose no lower than 15 mg/week.
Concomitant Strong CYP3A4 Inhibitors: The concomitant use of strong CYP3A4 inhibitors should be avoided (e.g. ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, and voriconazole). Grapefruit juice may also increase plasma concentrations of sirolimus (a major metabolite of temsirolimus) and should be avoided. If patients must be co-administered a strong CYP3A4 inhibitor, based on pharmacokinetic studies, a TORISEL dose reduction to 12.5 mg/week should be considered. This dose of TORISEL is predicted to adjust the AUC to the range observed without inhibitors. However, there are no clinical data with this dose adjustment in patients receiving strong CYP3A4 inhibitors. If the strong inhibitor is discontinued, a washout period of approximately 1 week should be allowed before the TORISEL dose is adjusted back to the dose used prior to initiation of the strong CYP3A4 inhibitor. [see DRUG INTERACTIONS]
Concomitant Strong CYP3A4 Inducers: The use of concomitant strong CYP3A4 inducers should be avoided (e.g. dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, rifampacin, phenobarbital). If patients must be co-administered a strong CYP3A4 inducer, based on pharmacokinetic studies, a TORISEL dose increase from 25 mg/week up to 50 mg/week should be considered. This dose of TORISEL is predicted to adjust the AUC to the range observed without inducers. However, there are no clinical data with this dose adjustment in patients receiving strong CYP3A4 inducers. If the strong inducer is discontinued the temsirolimus dose should be returned to the dose used prior to initiation of the strong CYP3A4 inducer. [see DRUG INTERACTIONS]
TORISEL must be stored under refrigeration at 2°-8°C (36°-46°F) and protected from light. During handling and preparation of admixtures, TORISEL should be protected from excessive room light and sunlight. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.
In order to minimize the patient exposure to the plasticizer DEHP (di-2-ethylhexyl phthalate), which may be leached from PVC infusion bags or sets, the final TORISEL dilution for infusion should be stored in bottles (glass, polypropylene) or plastic bags (polypropylene, polyolefin) and administered through polyethylene-lined administration sets.
Dilution:
In preparing the TORISEL administration solution, follow this two-step dilution process in an aseptic manner.
Step 1:
Inject 1.8 mL of DILUENT for TORISEL into the vial of TORISEL (temsirolimus) injection (25 mg/ml). The TORISEL (temsirolimus) vial contains an overfill of 0.2 mL (30 mg/1.2 mL). Due to the intentional overfill in the TORISEL injection vial, the drug concentration of the resulting solution will be 10 mg/mL. A total volume of 3 mL will be obtained including the overfill. Mix well by inversion of the vial. Allow sufficient time for air bubbles to subside. This 10 mg/mL drug solution/diluent mixture must be further diluted as described in Step 2 below.
The solution is clear to slightly turbid, colorless to yellow, and free from visual particulates. The 10 mg/mL drug solution/diluent mixture is stable for up to 24 hours at controlled room temperature.
Step 2:
Withdraw the required amount of temsirolimus from the 10 mg/mL drug solution/diluent mixture prepared in Step 1. Inject rapidly into a 250 mL container (glass, polyolefin, or polyethylene) of 0.9% sodium chloride injection. Mix the admixture by inversion of the bag or bottle. Avoid excessive shaking as this may cause foaming.
Administration:
Undiluted TORISEL injection should not be added directly to aqueous infusion solutions. Direct addition of TORISEL injection to aqueous solutions will result in precipitation of drug. Always combine TORISEL injection with DILUENT for TORISEL before adding to infusion solutions. It is recommended that TORISEL be administered in 0.9% sodium chloride injection after combining with diluent. The stability of TORISEL in other infusion solutions has not been evaluated. Addition of other drugs or nutritional agents to admixtures of TORISEL in sodium chloride injection has not been evaluated and should be avoided. Temsirolimus is degraded by both acids and bases, and thus combinations of temsirolimus with agents capable of modifying solution pH should be avoided.
TORISEL (temsirolimus) is supplied as a kit consisting of the following:
NDC 0008-1179-01 TORISEL (temsirolimus) injection, 25 mg/mL.
NDC 0008-1125-01 DILUENT for TORISEL, 1.8 mL (deliverable volume) per vial.
These two vials are supplied as a kit in a single carton, and must be stored at 2°-8°C (36°-46°F). Protect from light.
Manufactured for: Wyeth Pharmaceuticals Inc. Philadelphia, PA 19101
TORISEL (temsirolimus) injection is manufactured by: Pierre Fabre Medicament
Production, Aquitaine Pharm International, Avenue du Bearn, F64320 Idron, France
DILUENT for TORISEL is manufactured by: Ben Venue Laboratories, Inc., Bedford,
Ohio 44146-0568
FDA rev date: 5/30/2007
Last updated on RxList: 6/25/2007
The following serious adverse reactions have been associated with TORISEL in clinical trials and are discussed in greater detail in other sections of the label [see Warnings and PRECAUTIONS].
Hypersensitivity Reactions [see Warnings and PRECAUTIONS]
Hyperglycemia/Glucose Intolerance [see Warnings and PRECAUTIONS]
Interstitial Lung Disease [see Warnings and PRECAUTIONS]
Hyperlipemia [see Warnings and PRECAUTIONS]
Bowel Perforation [see Warnings and PRECAUTIONS]
Renal Failure (see Warnings and PRECAUTIONS]
The most common (≥ 30%) adverse reactions observed with TORISEL are rash, asthenia, mucositis, nausea, edema, and anorexia. The most common (≥ 30%) laboratory abnormalities observed with TORISEL are anemia, hyperglycemia, hyperlipemia, hypertriglyceridemia, lymphopenia, elevated alkaline phosphatase, elevated serum creatinine, hypophosphatemia, thrombocytopenia, elevated AST, and leukopenia.
Because clinical trials are conducted under widely varying conditions, the adverse reaction rates observed cannot be directly compared to rates in other trials and may not reflect the rates observed in clinical practice.
In the Phase 3 randomized, open-label study of interferon alfa (IFN-α) alone, TORISEL alone, and TORISEL and IFN-α, a total of 616 patients were treated. Two hundred patients received IFN-α weekly, 208 received TORISEL 25 mg weekly, and 208 patients received a combination of TORISEL and IFN-α weekly [see CLINICAL STUDIES)]
Treatment with the combination of TORISEL 15 mg and IFN-α was associated with an increased incidence of multiple adverse reactions and did not result in a significant increase in overall survival when compared with IFN-α alone.
Table 1 shows the percentage of patients experiencing treatment emergent adverse reactions. Reactions reported in at least 10% of patients who received TORISEL 25 mg alone or IFN-α alone are listed. Table 2 shows the percentage of patients experiencing selected laboratory abnormalities. Data for the same adverse reactions and laboratory abnormalities in the IFN-α alone arm are shown for comparison.
Table 1 -Adverse Reactions Reported in at Least 10% of Patients Who Received 25 mg IV TORISEL or IFN-α in the Randomized Trial
| Adverse Reaction | TORISEL 25 mg n=208 |
IFN-α n=200 |
||
| All Grades* n (%) |
Grades 3&4* n (%) |
All Grades* n (%) |
Grades 3&4* n (%) |
|
| Any | 208 (100) | 139 (67) | 199 (100) | 155 (78) |
| General disorders | ||||
| Asthenia | 106 (51) | 23 (11) | 127 (64) | 52 (26) |
| Edemaa | 73 (35) | 7 (3) | 21 (11) | 1 (1) |
| Pain | 59 (28) | 10 (5) | 31 (16) | 4 (2) |
| Pyrexia | 50 (24) | 1 (1) | 99 (50) | 7 (4) |
| Weight Loss | 39 (19) | 3 (1) | 50 (25) | 4 (2) |
| Headache | 31 (15) | 1 (1) | 30 (15) | 0 (0) |
| Chest Pain | 34 (16) | 2 (1) | 18 (9) | 2 (1) |
| Chills | 17 (8) | 1(1) | 59 (30) | 3 (2) |
| Gastrointestinal disorders | ||||
| Mucositisb | 86 (41) | 6 (3) | 19 (10) | 0 (0) |
| Anorexia | 66 (32) | 6 (3) | 87 (44) | 8 (4) |
| Nausea | 77 (37) | 5 (2) | 82 (41) | 9 (5) |
| Diarrhea | 56 (27) | 3 (1) | 40 (20) | 4 (2) |
| Abdominal Pain | 44 (21) | 9 (4) | 34 (17) | 3 (2) |
| Constipation | 42 (20) | 0 (0) | 36 (18) | 1 (1) |
| Vomiting | 40 (19) | 4 (2) | 57 (29) | 5 (3) |
| Infections | ||||
| Infectionsc | 42 (20) | 6 (3) | 19 (10) | 4 (2) |
| Urinary tract infectiond | 31 (15) | 3 (1) | 24 (12) | 3 (2) |
| Pharyngitis | 25 (12) | 0 (0) | 3 (2) | 0 (0) |
| Rhinitis | 20 (10) | 0 (0) | 4 (2) | 0 (0) |
| Musculoskeletal and connective tissue disorders | ||||
| Back Pain Arthralgia | 41 (20) 37 (18) | 6 (3) 2 (1) | 28 (14)29 (15) | 7 (4) 2 (1) |
| Any | 208 (100) | 139 (67) | 199 (100) | 155 (78) |
| Myalgia | 16 (8) | 1 (1) | 29 (15) | 2 (1) |
| Respiratory, thoracic and mediastinal disorders | ||||
| Dyspnea | 58 (28) | 18 (9) | 48 (24) | 11 (6) |
| Cough | 53 (26) | 2 (1) | 29 (15) | 0 (0) |
| Epistaxis | 25 (12) | 0 (0) | 7 (4) | 0 (0) |
| Skin and subcutaneous tissue disorders | ||||
| Rashe | 97 (47) | 10 (5) | 14 (7) | 0(0) |
| Pruritus | 40 (19) | 1 (1) | 16 (8) | 0 (0) |
| Nail Disorder | 28 (14) | 0 (0) | 1 (1) | 0 (0) |
| Dry Skin | 22 (11) | 1 (1) | 14 (7) | 0 (0) |
| Acne | 21 (10) | 0 (0) | 2 (1) | 0 (0) |
| Nervous system disorders | ||||
| Dysgeusiaf | 41 (20) | 0 (0) | 17 (9) | 0 (0) |
| Insomnia | 24 (12) | 1 (1) | 30 (15) | 0 (0) |
| Depression | 9 (4) | 0 (0) | 27 (14) | 4 (2) |
| * Common Terminology Criteria for Adverse
Events (CTCAE), Version 3.0. a Includes edema, facial edema, and peripheral edema b Includes aphthous stomatitis, glossitis, mouth ulceration, mucositis, and stomatitis c Includes infections not otherwise specified (NOS) and the following infections that occurred infrequently as distinct entities: abscess, bronchitis, cellulitis, herpes simplex, and herpes zoster d Includes cystitis, dysuria, hematuria, urinary frequency, and urinary tract infection e Includes eczema, exfoliative dermatitis, maculopapular rash, pruritic rash, pustular rash, rash (NOS), and vesiculobullous rash f Includes taste loss and taste perversion |
||||
The following selected adverse reactions were reported less frequently (< 10%).
Gastrointestinal Disorders - Fatal bowel perforation occurred in 1 patient (1%).
Eye Disorders - Conjunctivitis (including lacrimation disorder) occurred in 15 patients (7%).
Immune System - Allergic/Hypersensitivity reactions occurred in 18 patients (9%).
Angioneurotic edema-type reactions have been observed in some patients who received TORISEL and ACE inhibitors concomitantly.
Infections - Pneumonia occurred in 17 patients (8%); upper respiratory tract infection occurred in 14 patients (7%).
General Disorders and Administration Site Conditions - Impaired wound healing occurred in 3 patients (1%).
Respiratory, Thoracic and Mediastinal Disorders - Interstitial lung disease occurred in 5 patients (2%), including rare fatalities.
Vascular - Hypertension occurred in 14 patients (7%); venous thromboembolism (including deep vein thrombosis and pulmonary embolus) occurred in 5 patients (2%); thrombophlebitis occurred in 2 patients (1%).
Table 2 - Incidence of Selected Laboratory Abnormalities in Patients Who Received 25 mg IV TORISEL or IFN-α in the Randomized Trial
| Laboratory Abnormality | TORISEL 25 mg n=208 |
IFN-α n=200 |
||
| All Grades* n (%) |
Grades 3&4* n (%) |
All Grades* n (%) |
Grades 3&4* n (%) |
|
| Any | 208 (100) | 162 (78) | 195 (98) | 144 (72) |
| Hematology | ||||
| Hemoglobin Decreased | 195 (94) | 41 (20) | 180 (90) | 43 (22) |
| Lymphocytes Decreased** | 110 (53) | 33 (16) | 106 (53) | 48 (24) |
| Neutrophils Decreased** | 39 (19) | 10 (5) | 58 (29) | 19 (10) |
| Platelets Decreased | 84 (40) | 3 (1) | 51 (26) | 0 (0) |
| Leukocytes Decreased | 67 (32) | 1 (1) | 93 (47) | 11 (6) |
| Chemistry | ||||
| Alkaline Phosphatase Increased | 141 (68) | 7 (3) | 111 (56) | 13 (7) |
| AST Increased | 79 (38) | 5 (2) | 103 (52) | 14 (7) |
| Creatinine Increased | 119 (57) | 7 (3) | 97 (49) | 2 (1) |
| Glucose Increased | 186 (89) | 33 (16) | 128 (64) | 6 (3) |
| Phosphorus Decreased | 102 (49) | 38 (18) | 61 (31) | 17 (9) |
| Total Bilirubin Increased | 16 (8) | 2 (1) | 25 (13) | 4 (2) |
| Total Cholesterol Increased | 181 (87) | 5 (2) | 95 (48) | 2 (1) |
| Triglycerides Increased | 173 (83) | 92 (44) | 144 (72) | 69 (35) |
| Potassium Decreased | 43 (21) | 11 (5) | 15 (8) | 0 (0) |
| *NCI CTC version 3.0 **Grade 1 toxicity may be under-reported for lymphocytes and neutrophils |
||||
Co-administration of TORISEL with rifampin, a potent CYP3A4/5 inducer, had no significant effect on temsirolimus Cmax (maximum concentration) and AUC (area under the concentration versus the time curve) after intravenous administration, but decreased sirolimus Cmax by 65% and AUC by 56% compared to TORISEL treatment alone. If alternative treatment cannot be administered, a dose adjustment should be considered [See DOSAGE AND ADMINISTRATION].
Co-administration of TORISEL with ketoconazole, a potent CYP3A4 inhibitor, had no significant effect on temsirolimus Cmax or AUC; however, sirolimus AUC increased 3.1-fold, and Cmax increased 2.2-fold compared to TORISEL alone. If alternative treatment cannot be administered, a dose adjustment should be considered. [See DOSAGE AND ADMINISTRATION].
The concentration of desipramine, a CYP2D6 substrate, was unaffected when 25 mg of TORISEL was co-administered. No clinically significant effect is anticipated when temsirolimus is co-administered with agents that are metabolized by CYP2D6 or CYP3A4.
Last updated on RxList: 6/25/2007
Hypersensitivity reactions manifested by symptoms including, but not limited to, anaphylaxis, dyspnea, flushing, and chest pain have been observed with TORISEL.
TORISEL should be used with caution in persons with known hypersensitivity to temsirolimus or its metabolites (including sirolimus), polysorbate 80, or to any other component (including the excipients) of TORISEL.
An H1 antihistamine should be administered to patients before the start of the intravenous temsirolimus infusion. TORISEL should be used with caution in patients with known hypersensitivity to an antihistamine, or patients who cannot receive an antihistamine for other medical reasons.
If a patient develops a hypersensitivity reaction during the TORISEL infusion, the infusion should be stopped and the patient should be observed for at least 30 to 60 minutes (depending on the severity of the reaction). At the discretion of the physician, treatment may be resumed with the administration of an H1-receptor antagonist (such as diphenhydramine), if not previously administered [See DOSAGE AND ADMINISTRATION], and/or an H2-receptor antagonist (such as intravenous famotidine 20 mg or intravenous ranitidine 50 mg) approximately 30 minutes before restarting the TORISEL infusion. The infusion may then be resumed at a slower rate (up to 60 minutes).
The use of TORISEL is likely to result in increases in serum glucose. In the phase 3 trial, 89% of patients receiving TORISEL had at least one elevated serum glucose while on treatment, and 26% of patients reported hyperglycemia as an adverse event. This may result in the need for an increase in the dose of, or initiation of, insulin and/or oral hypoglycemic agent therapy. Serum glucose should be tested before and during treatment with TORISEL. Patients should be advised to report excessive thirst or any increase in the volume or frequency of urination.
The use of TORISEL may result in immunosuppression. Patients should be carefully observed for the occurrence of infections, including opportunistic infections [see ADVERSE REACTIONS].
Cases of interstitial lung disease, some resulting in death, occurred in patients who received TORISEL. Some patients were asymptomatic with infiltrates detected on computed tomography scan or chest radiograph. Others presented with symptoms such as dyspnea, cough, hypoxia, and fever. Some patients required discontinuation of TORISEL and/or treatment with corticosteroids and/or antibiotics, while some patients continued treatment without additional intervention. Patients should be advised to report promptly any new or worsening respiratory symptoms.
The use of TORISEL is likely to result in increases in serum triglycerides and cholesterol. In the phase 3 trial, 87% of patients receiving TORISEL had at least one elevated serum cholesterol value and 83% had at least one elevated serum triglyceride value. This may require initiation, or increase in the dose, of lipid-lowering agents. Serum cholesterol and triglycerides should be tested before and during treatment with TORISEL.
Cases of fatal bowel perforation occurred in patients who received TORISEL. These patients presented with fever, abdominal pain, metabolic acidosis, bloody stools, diarrhea, and/or acute abdomen. Patients should be advised to report promptly any new or worsening abdominal pain or blood in their stools.
Cases of rapidly progressive and sometimes fatal acute renal failure not clearly related to disease progression occurred in patients who received TORISEL. Some of these cases were not responsive to dialysis.
Use of TORISEL has been associated with abnormal wound healing. Therefore, caution should be exercised with the use of TORISEL in the perioperative period.
Patients with central nervous system tumors (primary CNS tumor or metastases) and/or receiving anticoagulation therapy may be at an increased risk of developing intracerebral bleeding (including fatal outcomes) while receiving TORISEL.
Strong inducers of CYP3A4/5 such as dexamethasone, carbamazepine, phenytoin, phenobarbital, rifampin, rifabutin, and rifampacin may decrease exposure of the active metabolite, sirolimus. If alternative treatment cannot be administered, a dose adjustment should be considered. St. John's Wort may decrease TORISEL plasma concentrations unpredictably. Patients receiving TORISEL should not take St. John's Wort concomitantly. [See DOSAGE AND ADMINISTRATION and DRUG INTERACTIONS].
Strong CYP3A4 inhibitors such as atazanavir, clarithromycin, indinavir, itraconazole, ketoconazole, nefazodone, nelfinavir, ritonavir, saquinavir, and telithromycin may increase blood concentrations of the active metabolite sirolimus. If alternative treatments cannot be administered, a dose adjustment should be considered. [See DOSAGE AND ADMINISTRATION and DRUG INTERACTIONS].
The combination of TORISEL and sunitinib resulted in dose-limiting toxicity. Dose-limiting toxicities (Grade 3/4 erythematous maculopapular rash, and gout/cellulitis requiring hospitalization) were observed in two out of three patients treated in the first cohort of a phase 1 study at doses of TORISEL 15 mg IV per week and sunitinib 25 mg oral per day (Days 1-28 followed by a 2-week rest).
The use of live vaccines and close contact with those who have received live vaccines should be avoided during treatment with TORISEL. Examples of live vaccines are: intranasal influenza, measles, mumps, rubella, oral polio, BCG, yellow fever, varicella, and TY21a typhoid vaccines.
Temsirolimus administered daily as an oral formulation caused embryo-fetal and intrauterine toxicities in rats and rabbits at human sub-therapeutic exposures. Embryo-fetal adverse effects in rats consisted of reduced fetal weight and reduced ossifications, and in rabbits included reduced fetal weight, omphalocele, bifurcated sternabrae, notched ribs, and incomplete ossifications.
In rats, the intrauterine and embryo-fetal adverse effects were observed at the oral dose of 2.7 mg/m2/day (approximately 0.04-fold the AUC in cancer patients at the human recommended dose). In rabbits, the intrauterine and embryo-fetal adverse effects were observed at the oral dose of ≥ 7.2 mg/m2/day (approximately 0.12-fold the AUC in cancer patients at the recommended human dose).
Women of childbearing potential should be advised to avoid becoming pregnant throughout treatment and for 3 months after TORISEL therapy has stopped. Temsirolimus can cause fetal harm when administered to a pregnant woman. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus.
Men should be counseled regarding the effects of TORISEL on the fetus and sperm prior to starting treatment [see Nonclinical Toxicology]. Men with partners of childbearing potential should use reliable contraception throughout treatment and are recommended to continue this for 3 months after the last dose of TORISEL.
In the randomized, phase 3 trial, complete blood counts (CBCs) were checked weekly, and chemistry panels were checked every two weeks. Laboratory monitoring for patients receiving TORISEL may need to be performed more or less frequently at the physician's discretion.
Carcinogenicity studies have not been conducted with temsirolimus. However, sirolimus, the major metabolite of temsirolimus in humans, was carcinogenic in mice and rats. The following effects were reported in mice and/or rats in the carcinogenicity studies conducted with sirolimus: lymphoma, hepatocellular adenoma and carcinoma, and testicular adenoma.
Temsirolimus was not genotoxic in a battery of in vitro (bacterial reverse mutation in Salmonella typhimurium and Escherichia coli, forward mutation in mouse lymphoma cells, and chromosome aberrations in Chinese hamster ovary cells) and in vivo (mouse micronucleus) assays.
In male rats, the following fertility effects were observed: decreased number of pregnancies, decreased sperm concentration and motility, decreased reproductive organ weights, and testicular tubular degeneration. These effects were observed at oral temsirolimus doses ≥ 3 mg/m2/day (approximately 0.2-fold the human recommended intravenous dose). Fertility was absent at 30 mg/m2/day.
In female rats, an increased incidence of pre- and post-implantation losses occurred at oral doses ≥ 4.2 mg/m2/day (approximately 0.3-fold the human recommended intravenous dose), resulting in decreased numbers of live fetuses.
Pregnancy Category D [see Warnings and PRECAUTIONS].
It is not known whether TORISEL is excreted into human milk, and due to the potential for tumorigenicity shown for sirolimus (active metabolite of TORISEL) in animal studies, a decision should be made whether to discontinue nursing or discontinue TORISEL, taking into account the importance of the drug to the mother.
The safety and effectiveness of TORISEL in pediatric patients have not been established.
Clinical studies of TORISEL did not include sufficient numbers of subjects aged 65 and older to determine whether they respond differently from younger subjects.
No clinical studies were conducted with TORISEL in patients with decreased renal function. Less than 5% of total radioactivity was excreted in the urine following a 25 mg intravenous dose of [14C]-labeled temsirolimus in healthy subjects. Renal impairment is not expected to markedly influence drug exposure, and no dosage adjustment of TORISEL is recommended in patients with renal impairment.
TORISEL has not been studied in patients undergoing hemodialysis.
Temsirolimus is cleared predominantly by the liver. No data are currently available regarding the influence of hepatic dysfunction on temsirolimus disposition.
Last updated on RxList: 6/25/2007
There is no specific treatment for TORISEL intravenous overdose. TORISEL has been administered to patients with cancer in phase 1 and 2 trials with repeated intravenous doses as high as 220 mg/m2. The risk of several serious adverse events, including thrombosis, bowel perforation, interstitial lung disease (ILD), seizure, and psychosis, is increased with doses of TORISEL greater than 25 mg.
Temsirolimus is an inhibitor of mTOR (mammalian target of rapamycin). Temsirolimus binds to an intracellular protein (FKBP-12), and the protein-drug complex inhibits the activity of mTOR that controls cell division. Inhibition of mTOR activity resulted in a G1 growth arrest in treated tumor cells. When mTOR was inhibited, its ability to phosphorylate p70S6k and S6 ribosomal protein, which are downstream of mTOR in the PI3 kinase/AKT pathway was blocked. In in vitro studies using renal cell carcinoma cell lines, temsirolimus inhibited the activity of mTOR and resulted in reduced levels of the hypoxia-inducible factors HIF-1 and HIF-2 alpha, and the vascular endothelial growth factor.
Following administration of a single 25 mg dose of TORISEL in patients with cancer, mean temsirolimus Cmax in whole blood was 585 ng/mL (coefficient of variation, CV =14%), and mean AUC in blood was 1627 ng•h/mL (CV=26%). Typically Cmax occurred at the end of infusion. Over the dose range of 1 mg to 25 mg, temsirolimus exposure increased in a less than dose proportional manner while sirolimus exposure increased proportionally with dose. Following a single 25 mg intravenous dose in patients with cancer, sirolimus AUC was 2.7-fold that of temsirolimus AUC, due principally to the longer half-life of sirolimus.
Following a single 25 mg intravenous dose, mean steady-state volume of distribution of temsirolimus in whole blood of patients with cancer was 172 liters. Both temsirolimus and sirolimus are extensively partitioned into formed blood elements.
Cytochrome P450 3A4 is the major isozyme responsible for the formation of five temsirolimus metabolites. Sirolimus, an active metabolite of temsirolimus, is the principal metabolite in humans following intravenous treatment. The remainder of the metabolites account for less than 10% of radioactivity in the plasma. In human liver microsomes temsirolimus was an inhibitor of CYP2D6 and 3A4. However, there was no effect observed in vivo when temsirolimus was administered with desipramine (a CYP2D6 substrate), and no effect is anticipated with substrates of CYP3A4 metabolism.
Elimination is primarily via the feces. After a single IV dose of [14C]-temsirolimus approximately 82% of total radioactivity was eliminated within 14 days, with 4.6% and 78% of the administered radioactivity recovered in the urine and feces, respectively. Following a single 25 mg dose of TORISEL in patients with cancer, temsirolimus mean (CV) systemic clearance was 16.2 (22%) L/h. Temsirolimus exhibits a bi-exponential decline in whole blood concentrations and the mean half-lives of temsirolimus and sirolimus were 17.3 hr and 54.6 hr, respectively.
In population pharmacokinetic-based data analyses, no relationship was apparent between drug exposure and patient age or gender.
A phase 3, multi-center, three-arm, randomized, open-label study was conducted in previously untreated patients with advanced renal cell carcinoma (clear cell and non-clear cell histologies). The objectives were to compare Overall Survival (OS), Progression-Free Survival (PFS), Objective Response Rate (ORR), and safety in patients receiving IFN-α to those receiving TORISEL or TORISEL plus IFN-α. Patients in this study had 3 or more of 6 pre-selected prognostic risk factors (less than one year from time of initial RCC diagnosis to randomization, Karnofsky performance status of 60 or 70, hemoglobin less than the lower limit of normal, corrected calcium of greater than 10 mg/dL, lactate dehydrogenase > 1.5 times the upper limit of normal, more than one metastatic organ site). Patients were stratified for prior nephrectomy status within three geographic regions and were randomly assigned (1:1:1) to receive IFN-α alone (n=207), TORISEL alone (25 mg weekly; n=209), or the combination arm (n=210).
The ITT population for this interim analysis included 626 patients. Demographics were comparable between the three treatment arms with regard to age, gender, and race. The mean age of all groups was 59 years (range 23-86). Sixty-nine percent were male and 31% were female. The racial distribution for all groups was 91% White, 4% Black, 2% Asian, and 3% other. Sixty-seven percent of patients had a history of prior nephrectomy.
The median duration of treatment in the TORISEL arm was 17 weeks (range 1-126 weeks). The median duration of treatment on the IFN arm was 8 weeks (range 1-124 weeks).
There was a statistically significant improvement in OS (time from randomization to death) in the TORISEL 25 mg arm compared to IFN-α. The combination of TORISEL 15 mg and IFN-α did not result in a significant increase in overall survival when compared with IFN-α alone. Figure 1 is a Kaplan-Meier plot of OS in this study. The evaluations of PFS (time from randomization to disease progression or death) and ORR, were based on blinded independent radiologic assessment of tumor response. Efficacy results are summarized in Table 3.
Table 3: Summary of Efficacy Results of TORISEL vs. IFN-α
| Parameter | TORISEL n = 209 |
IFN-α n = 207 |
P-valuea | Hazard Ratio (95% CI)b |
| Median Overall Survival Months (95% CI) |
10.9 (8.6, 12.7) | 7.3 (6.1, 8.8) | 0.0078* | 0.73 (0.58, 0.92) |
| Median Progression-Free Survival Months (95% CI) |
5.5 (3.9, 7.0) | 3.1 (2.2, 3.8) | 0.0001** | 0.66 (0.53, 0.81) |
| Overall Response Rate % (95% CI) |
8.6 (4.8, 12.4) | 4.8 (1.9, 7.8) | 0.1232**c | NA |
| CI = confidence interval; NA = not applicable * A comparison is considered statistically significant if the p-value is < 0.0159 (O'Brien-Fleming boundary at 446 deaths). ** Not adjusted for multiple comparisons. a. Based on log-rank test stratified by prior nephrectomy and region. b. Based on Cox proportional hazard model stratified by prior nephrectomy and region. c. Based on Cochran-Mantel-Haenszel test stratified by prior nephrectomy and region. |
||||
 |
REFERENCES
1. NIOSH Alert: Preventing occupational exposures to antineoplastic
and other hazardous drugs in healthcare settings. 2004. U.S. Department of Health
and Human Services, Public Health Service, Centers for Disease Control and Prevention,
National Institute for Occupational Safety and Health, DHHS (NIOSH) Publication
No. 2004-165.
2. OSHA Technical Manual, TED 1-0.15A, Section VI: Chapter 2. Controlling
Occupational Exposure to Hazardous Drugs. OSHA, 1999. http://www.osha.gov/dts/osta/otm/otm_vi/otm_vi_2.html
3. NIH [2002]. 1999 recommendations for the safe handling of cytotoxic
drugs. U.S. Department of Health and Human Services, Public Health Service,
National Institutes of Health, NIH Publication No. 92-2621.
4. American Society of Health-System Pharmacists. (2006) ASHP Guidelines
on Handling Hazardous Drugs.
5. Polovich, M., White, J. M., & Kelleher, L.O. (eds.) 2005.
Chemotherapy and biotherapy guidelines and recommendations for practice (2nd.
ed.) Pittsburgh, PA: Oncology Nursing Society.
Last updated on RxList: 6/25/2007
Patients should be informed of the possibility of serious allergic reactions, including anaphylaxis, despite premedication with antihistamines, and to immediately report any facial swelling or difficulty breathing [see Warnings and PRECAUTIONS].
Patients are likely to experience increased blood glucose levels while taking TORISEL. This may result in the need for initiation of, or increase in the dose of, insulin and/or hypoglycemic agents. Patients should be directed to report any excessive thirst or frequency of urination to their physician [see Warnings and PRECAUTIONS].
Patients should be informed that they may be more susceptible to infections while being treated with TORISEL [see Warnings and PRECAUTIONS].
Patients should be warned of the possibility of developing interstitial lung disease, a chronic inflammation of the lungs, which may rarely result in death [see Warnings and PRECAUTIONS]. Patients should be directed to report promptly any new or worsening respiratory symptoms to their physician.
Patients are likely to experience elevated triglycerides and/or cholesterol during TORISEL treatment. This may require initiation of, or increase in the dose of, lipid-lowering agents [see Warnings and PRECAUTIONS].
Patients should be warned of the possibility of bowel perforation. Patients should be directed to report promptly any new or worsening abdominal pain or blood in their stools [see Warnings and PRECAUTIONS].
Patients should be informed of the risk of renal failure [see Warnings and PRECAUTIONS].
Patients should be advised of the possibility of abnormal wound healing if they have surgery within a few weeks of initiating therapy or during therapy [see Warnings and PRECAUTIONS].
Patients with CNS tumors and/or receiving anticoagulants should be informed of the increased risk of developing intracerebral bleeding (including fatal outcomes) while on TORISEL [see Warnings and PRECAUTIONS].
Some medicines can interfere with the breakdown or metabolism of TORISEL. In particular, patients should be directed to inform their physician if they are taking any of the following: Protease inhibitors, anti-epileptic medicines including carbamazepine, phenytoin, and barbiturates, St. John's Wort, rifampicin, rifabutin, nefazodone or selective serotonin re-uptake inhibitors used to treat depression, antibiotics or antifungal medicines used to treat infections [see Warnings and PRECAUTIONS].
Patients should be advised that vaccinations may be less effective while being treated with TORISEL. In addition, the use of live vaccines, and close contact with those who have received live vaccines, while on TORISEL should be avoided. [see Warnings and PRECAUTIONS].
TORISEL can cause fetal harm. Women of childbearing potential should be advised to avoid becoming pregnant throughout treatment and for 3 months after TORISEL therapy has stopped. Men with partners of childbearing potential should use reliable contraception throughout treatment and are recommended to continue this for 3 months after the last dose of TORISEL. [see Warnings and PRECAUTIONS]
Last updated on RxList: 6/25/2007
IMPORTANT NOTE: This is a summary and does not contain all possible information about this product. For complete information about this product or your specific health needs, ask your health care professional. Always seek the advice of your health care professional if you have any questions about this product or your medical condition. This information is not intended as individual medical advice and does not substitute for the knowledge and judgment of your health care professional. This information does not contain any assurances that this product is safe, effective, or appropriate for you.
TEMSIROLIMUS - INJECTION
(tem-sir-oh-LEE-muss)
COMMON BRAND NAME(S): Torisel
USES: This medication is used to treat kidney cancer. It works by slowing or stopping the growth of cancer cells.
HOW TO USE: This medication is given by injection into a vein by a health care professional. It is usually given once a week (over 30 to 60 minutes) or as directed by your doctor. Health care professionals must follow all the manufacturer's instructions for properly mixing and giving this drug, as well as watching for infusion reactions (see Side Effects section). Before using, check this product visually for particles or discoloration. If either is present, do not use the liquid. If you have any questions about using this medication properly, consult your doctor or pharmacist.
The dosage is based on your medical condition, interacting drugs, and response to treatment.
Your doctor may direct you to receive another medication (e.g., diphenhydramine) before the injection to help prevent side effects (infusion reactions).
Use this medication regularly to get the most benefit from it. To help you remember, mark the days on the calendar when you need to receive the medication.
Avoid eating grapefruit or drinking grapefruit juice while being treated with this medication unless your doctor instructs you otherwise. Grapefruit can increase the amount of certain medications in your bloodstream. Consult your doctor or pharmacist for more details.
Many people using this medication have serious side effects. However, your doctor has prescribed this drug because he or she has judged that the benefit to you is greater than the risk of side effects. Careful monitoring by your doctor may decrease your risk.
Tell your doctor immediately if any of these serious side effects occur: flushing, slow wound healing, swelling ankles/feet, eye redness/itching, easy bruising/bleeding, unusual tiredness, muscle cramps, fast/pounding heartbeat, pain/redness/swelling of arms or legs.
This medication can lower the body's ability to fight an infection. Tell your doctor promptly if you develop any signs of an infection such as fever, chills, or persistent sore throat.
Temsirolimus may cause your cholesterol/triglycerides or blood sugar to increase. You may be required to have your cholesterol/triglycerides or blood sugar checked periodically. You may need medication to control your cholesterol/triglycerides or blood sugar. Tell your doctor or pharmacist if you experience symptoms of high blood sugar, including increased thirst/hunger, frequent urination.
This medication can infrequently cause serious (rarely fatal) lung, kidney, or intestinal problems. Tell your doctor immediately if you notice any symptoms of lung, kidney, or intestinal problems, including: shortness of breath, cough, change in the amount of urine, severe abdominal pain, black/bloody stool.
Infrequently a very serious allergic reaction to this drug might occur, especially while your dose is being given (infusion reaction). Seek immediate medical attention if you notice any of the following symptoms of a serious allergic reaction: rash/flushing, itching/swelling (especially of the face/tongue/lips/throat), severe dizziness, chest pain, trouble breathing.
Temsirolimus can commonly cause a mild rash that is usually not serious. However, you may not be able to tell it apart from a rare rash that could be a sign of a severe allergic reaction. Therefore, seek immediate medical attention if you develop any rash.
This is not a complete list of possible side effects. If you notice other effects not listed above, contact your doctor or pharmacist.
Contact your doctor for medical advice about side effects. The following numbers do not provide medical advice, but in the US you may report side effects to the Food and Drug Administration (FDA) at 1-800-FDA-1088. In Canada, you may call Health Canada at 1-866-234-2345.
PRECAUTIONS: Before receiving temsirolimus, tell your doctor or pharmacist if you are allergic to it; or to sirolimus; or if you have any other allergies.
Before using this medication, tell your doctor or pharmacist your medical history, especially of: diabetes, high cholesterol/triglyceride levels, liver disease, kidney disease, recent/current infections or wounds, recent surgery, brain cancer.
Do not have immunizations/vaccinations without the consent of your doctor, and avoid contact with people who have recently received oral polio vaccine or flu vaccine inhaled through the nose. Wash your hands well to prevent the spread of infections.
Before having surgery, tell your doctor or dentist that you are using this medication.
Pain or sores in the mouth and throat may occur. Brush your teeth gently/carefully, avoid using mouthwash that contains alcohol, and rinse your mouth frequently with cool water mixed with baking soda or salt. It may also be best to eat soft, moist foods.
This drug is not recommended for use during pregnancy. It may harm an unborn baby. Consult your doctor for more details. It is recommended that both men and women receiving this medication use at least 2 reliable forms of birth control (e.g., condoms, birth control pills) during treatment with this medication and for at least 3 months afterwards. If you become pregnant or think you may be pregnant, or if your partner becomes pregnant, tell your doctor immediately.
It is not known if this drug passes into breast milk. Because of the possible risk to the infant, breast-feeding while using this drug is not recommended. Consult your doctor before breast-feeding.
Your doctor or pharmacist may already be aware of any possible drug interactions and may be monitoring you for them. Do not start, stop, or change the dosage of any medicine before checking with them first.
Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription/herbal products you may use, especially of: ACE inhibitors (e.g., lisinopril), "blood thinners" (e.g., warfarin, enoxaparin), drugs affecting liver enzymes that remove temsirolimus from your body (such as nefazodone, dexamethasone, St. John's wort, azole antifungals including itraconazole, macrolide antibiotics including erythromycin , HIV protease inhibitors including ritonavir, rifamycins including rifabutin, calcium channel blockers such as verapamil/nifedipine, certain anti-seizure medicines including carbamazepine/phenytoin/phenobarbital), drugs that may weaken the immune system (e.g., cyclosporine, sirolimus), sunitinib.
This document does not contain all possible interactions. Therefore, before using this product, tell your doctor or pharmacist of all the products you use. Keep a list of all your medications with you, and share the list with your doctor and pharmacist.
OVERDOSE: If overdose is suspected, contact your local poison control center or emergency room immediately. US residents can call the US National Poison Hotline at 1-800-222-1222. Canada residents can call a provincial poison control center. Symptoms of overdose may include: seizures, mental/mood changes, trouble breathing.
NOTES: Do not share this medication with others.
Laboratory and/or medical tests (e.g., complete blood count, cholesterol/triglyceride levels, blood glucose levels, liver/kidney function) should be performed periodically to monitor your progress or check for side effects. Consult your doctor for more details.
MISSED DOSE: For the best possible benefit, it is important to receive each scheduled dose of this medication as directed. If you miss a dose, contact your doctor to establish a new dosing schedule.
STORAGE: Refrigerate the kit between 36-46 degrees F (2-8 degrees C) away from light. The mixed medication is stable for up to 24 hours if stored at room temperature. After diluting the medication, use or discard within 6 hours. Keep all medicines away from children and pets.
Do not flush medications down the toilet or pour them into a drain unless instructed to do so. Properly discard this product when it is expired or no longer needed. Consult your pharmacist or local waste disposal company for more details about how to safely discard your product.
MEDICAL ALERT: Your condition can cause complications in a medical emergency. For information about enrolling in MedicAlert, call 1-800-854-1166 (USA) or 1-800-668-1507 (Canada).
Information last revised August 2008 Copyright(c) 2008 First DataBank, Inc.
Here is a collection of user reviews for the medication Torisel sorted by most helpful. 
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.
 |
RxList does not provide medical advice, diagnosis or treatment. See additional information.
Updated & New